Peter G. Sørensen

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian Cancer

Jan P. Neijt, Svend Aage Engelholm, Malgorzata Tuxen et al. · Journal of Clinical Oncology · 2000 · 441 citations

Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study

Michael Andersson, Elisabeth Lidbrink, Karsten Bjerre et al. · Journal of Clinical Oncology · 2010 · 291 citations

Prolonged bone marrow T1-relaxation in acute leukaemia. In vivo tissue characterization by magnetic resonance imaging

Carsten Thomsen, Peter G. Sørensen, Hans Karle et al. · Magnetic Resonance Imaging · 1987 · 62 citations

Hematological Malignancy, Acute Leukaemia, Health Sciences +13

Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF Combination with epirubicin

Henning T. Mouridsen, J.C. Andersen, Michael Andersson et al. · European Journal of Cancer · 1999 · 62 citations

Cmf Combination, Surgical Oncology, Oncology +8